©2026 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy
DURAVYU™ (vorolanib intravitreal insert)

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Show Description +

Durga S. Borkar, MD, MMCi, and Jayanth Sridhar, MD, highlight why visual acuity outcomes in the real world differ from those in clinical trials and why a new class of treatment for wet age-related macular degeneration and diabetic macular edema is needed.

Posted: 5/16/2025

Keywords:

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Clinical Trials

•

EyePoint Pharmaceuticals

•

EYP-1901

•

TKI

•

tyrosine-kinase inhibitor

•

vorolanib

•

DURAVYU

•

An overview of TKIs and how they may fit into the wAMD treatment regimen

Up Next

Wet AMD and DME Therapy in Development
Wet AMD and DME Therapy in Development

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

An overview of TKIs and how they may fit into the wAMD treatment regimen

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?
Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Wet AMD and DME Therapy in Development
Wet AMD and DME Therapy in Development

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

TKIs: How Do They Work?
TKIs: How Do They Work?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?
What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

What Evidence Makes EYP-1901 a Potential Treatment for Wet AMD and DME?
What Evidence Makes EYP-1901 a Potential Treatment for Wet AMD and DME?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

How Can a Multi-MOA Approach Benefit the Management of Wet AMD?
How Can a Multi-MOA Approach Benefit the Management of Wet AMD?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Reinjection Criteria
Reinjection Criteria

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Patient Selection for EYP-1901
Patient Selection for EYP-1901

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Additional Videos

EYP1901 Mechanism of Action
EYP1901 Mechanism of Action

link-arrow   Back to All Videos

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Durga S. Borkar, MD, MMCi, and Jayanth Sridhar, MD, highlight why visual acuity outcomes in the real world differ from those in clinical trials and why a new class of treatment for wet age-related macular degeneration and diabetic macular edema is needed.

Posted: 5/16/2025

Keywords:

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Clinical Trials

•

EyePoint Pharmaceuticals

•

EYP-1901

•

TKI

•

tyrosine-kinase inhibitor

•

vorolanib

•

DURAVYU

•

An overview of TKIs and how they may fit into the wAMD treatment regimen

Resources

Addressing the Gaps in Duration of Treatment for Age-Related Macular Degeneration

View Resource

Scientific Publications image

Scientific Publications

View Resource

Image Gallery

Duravyu MOA

About EyePoint, Inc

EYP-1901 is an investigational product and the safety and efficacy of EYP-1901 has not been established. FDA has not approved EYP-1901 in the United States. The materials discussed on this site do not predict future FDA approval. Conclusive evidence of efficacy and safety of EYP-1901 will require further investigation in well-controlled Phase 3 clinical trials

Visit us online: eyepointpharma.com

Follow EyePoint, Inc

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU™ is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

DURAVYU (EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™ - efficacy and safety have not yet been established with well controlled, phase 3 pivotal trials.